Eisai has announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), held both virtually and in-person in Chicago, Illinois from May 31 to June 4. They are presenting research from their oncology portfolio and…
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have announced the publication of groundbreaking findings in Nature Communications, revealing the results from a comprehensive phase 1/2/3a/3b study investigating the safety, immune response, and effectiveness of ARCT-154, a pioneering self-amplifying (sa-mRNA)…
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative developed in collaboration with the schizophrenia community. The campaign aims to amplify firsthand experiences and equip patients and caregivers with educational tools, community connections, and…
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative in collaboration with the schizophrenia community. The campaign aims to amplify personal experiences, offering educational resources, community connections, and peer support to empower patients and…
Eli Lilly’s Mirikizumab Shows Promise in Phase 3 Study for Crohn’s Disease In Eli Lilly and Company’s pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn’s disease, regardless of previous biologic failure, showed significant and meaningful improvements…
Guardant Health, Inc. (Nasdaq: GH), a prominent player in precision oncology, disclosed today that its Compensation Committee, on April 22, 2024, sanctioned the allocation of restricted stock units (“RSUs”) corresponding to 215,601 shares of its common stock for 94 newly…
MAIA Biotechnology, Inc. (NYSE American: MAIA), a pioneering company focused on developing immunotherapies targeting telomeres for cancer treatment, has confirmed its participation in the prestigious BIO International Convention scheduled from June 3 to June 6, 2024, in San Diego, California.…
The latest addition to ResearchAndMarkets.com’s offerings is the “Reproductive Hormones and Proteins Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033” report. This insightful analysis delves into the Reproductive Hormones and Proteins Tests Market, projecting trends and…
Aiming to advance treatment options for seizure disorders, Marinus Pharmaceuticals has successfully completed enrollment in the global Phase 3 TrustTSC trial. This trial assesses oral ganaxolone’s efficacy in managing seizures associated with tuberous sclerosis complex (TSC) across various age groups.…
Azitra, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for precision dermatology, has unveiled preclinical findings from its cutting-edge platform and pipeline. These findings are being presented at the Society of Investigative Dermatology (SID) 2024 Annual Meeting in…
The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, highlighting 15 families of antibiotic-resistant bacteria grouped into critical, high, and medium categories for prioritization. This list serves as a compass for the development…
A spatial AI biomarker company specializing in deciphering cellular conversations and mapping cellular interactions within tissue samples to predict therapeutic outcomes has announced the expansion of its executive leadership team. Nucleai revealed today the appointment of Vikas Ahuja as Vice…